• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

LRP5 Antibody – Rabbit Polyclonal

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS462068

Low-desnsity lipoprotein receptor (LDLR)-related protein 5 (LRP5) is a member of the LDLR family which consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. LRP5 cuases several human diseases including bone mineral… More details

$355 / 0.1 mg +1 FREE 8GB USB
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
LRP5 (pT1492), Polyclonal Antibody
Full Product Name
Rabbit anti LRP5 (pT1492)
Product Gene Name
Product Synonym Names
Rabbit anti LRP5 Phospho-specific antibody; Low-density lipoprotein Receptor-related Protein 5 (LRP5); LR3.
Clonality
Polyclonal
Host
Rabbit
Species Reactivity
Human, rat, mouse
Form/Format
This affinity purified antibody is supplied in sterile Phosphatebuffered saline (pH7.2) containing antibody stabilizer
Purity/Purification
The rabbit IgG is purified by Site-specific Epitope Affinity Purification.
Concentration
100 ug/200 ul (lot specific)
Specificity
This antibody recognizes ~175 kDa of human LRP5 protein. It also reacts with mouse and rat. The other species are not tested.
Preparation and Storage
The antibodies are stable for 12 months from date of receipt when stored at -20 degree C to -70 degree C. The antibodies can be stored at 2 degree C to 8 degree C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.
Molecular Weight
175 kDa
Chromosome Location
Chromosome: 11; NC_000011.9 (68080108..68216743). Location: 11q13.4
OMIM
144750
3D Structure
ModBase 3D Structure for O75197
Antigen Preparation
A synthetic peptide corresponding to the epitope KATLY at a phosphorylation threonine1492 in LRP5 protein
Positive Control
LRP5 transfected HEK293
Applications Tested/Suitable for anti-LRP5 antibody
ELISA, Western Blot, Immunohistochemistry
Application Notes for anti-LRP5 antibody
Suggested Dilution:
Western Blot: 0.1-1 ug/ml
ELISA: 0.01-0.1 ug/ml
Immunoprecipitation: 2-5 ug/ml
Immunohistochemistry: 2-5 ug/ml

Testing Data of anti-LRP5 antibody

Rabbit Anti-LRP5 Polyclonal Antibody – Cat# MBS462068

Testing Data 2 of anti-LRP5 antibody

Rabbit Anti-LRP5 Polyclonal Antibody, Testing Data 2 – Cat# MBS462068

Product References and Citations for anti-LRP5 antibody

• Davidson, G. et al. (2005), Nature 438, 867-872

Other Notes

Small volumes of anti-LRP5 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for LRP5 purchase

Low-density lipoprotein receptor 5 LRP 5 is a member of lipoprotein receptors. Functionally involved in canonical Wnt signaling, loss or gain of function results in bone reductions or deformations. To further understand mechanisms in receptor related signaling pathway dysfunctions, the availability of a specific rabbit anti human LRP5 protein is key for immunohistochemistry IHC, western blot or as part of antibody pairs for ELISA studies. This LRP5 antibody has been site specific purified and compares well to a known rabbit mAb monoclonal antibody. Additionally, (Abgent) our manufacturer recommendations include optimal dilutions for this rabbit IgG polyclonal antibody in defined buffer conditions and provides documentation that no binding of related protein or combined LRP5 LRP6 complex occurs. Trust your cell samples to all our antibodies, whether its a human mouse rat or anti rabbit species low density lipoprotein receptor or receptor related protein. Order rabbit anti LRP5 PT1492 today at MyBiosource.com.

Additional Details

NCBI/Uniprot data below describe general gene information for LRP5. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
low-density lipoprotein receptor-related protein 5
NCBI Official Synonym Full Names
low density lipoprotein receptor-related protein 5
NCBI Official Symbol
LRP5
NCBI Official Synonym Symbols
HBM; LR3; OPS; EVR1; EVR4; LRP7; OPPG; BMND1; OPTA1; VBCH2
UniProt Protein Name
Low-density lipoprotein receptor-related protein 5
UniProt Gene Name
LRP5
UniProt Synonym Gene Names
LRP7
UniProt Entry Name
LRP5_HUMAN
NCBI Protein Information
low-density lipoprotein receptor-related protein 5; LRP-5; OTTHUMP00000236183; low density lipoprotein receptor-related protein 7

NCBI Summary for LRP5

This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy. [provided by RefSeq]
Show more

UniProt Comments for LRP5

Function: Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Appears be required for postnatal control of vascular regression in the eye. Required for posterior patterning of the epiblast during gastrulation. Ref.5 Ref.6 Ref.7 Ref.8 Ref.21

Subunit structure: Homodimer; disulfide-linked. Forms phosphorylated oligomer aggregates on Wnt-signaling

By similarity. Component of a Wnt-signaling complex that contains a WNT protein, a FZD protein and LRP5 or LRP6. Interacts with FZD8; the interaction is formed on WNT-binding and signaling. Interacts (via the phosphorylated PPPSP motif domains) with AXIN1; the interaction prevents inhibition of beta-catenin phosphorylation and signaling and is enhanced in the presence of GSK3B and WNT1 or WNT3A. Interacts (via beta-propeller regions 3 and 4) with DKK1; the interaction, enhanced by MESD and/or KREMEN, inhibits beta-catenin signaling by preventing GSK3-mediated phosphorylation of the PPPSP motifs and subsequent, AXIN1 binding. Interacts with MESD; the interaction prevents the formation of LRP5 aggregates, targets LRP5 to the plasma membrane and, when complexed with KREMEN2, increases DKK1 binding. Interacts with CSNK1E. Interacts with SOST; the interaction antagonizes canonical Wnt signaling. Interacts with APCDD1. Ref.5 Ref.6 Ref.7 Ref.8 Ref.9 Ref.10 Ref.11 Ref.12 Ref.13

Subcellular location: Membrane; Single-pass type I membrane protein. Endoplasmic reticulum

By similarity. Note: Chaperoned to the plasma membrane by MESD

Tissue specificity: Widely expressed, with the highest level of expression in the liver.

Post-translational modification: Phosphorylation of cytoplasmic PPPSP motifs regulates the signal transduction of the Wnt signaling pathway through acting as a docking site for AXIN1

Polymorphism: Genetic variations in LRP5 define the bone mineral density quantitative trait locus 1 (BMND1) [

MIM:601884]. Variance in bone mineral density influences bone mass and contributes to size determination in the general population.

Involvement in disease: Defects in LRP5 are the cause of vitreoretinopathy exudative type 4 (EVR4) [

MIM:601813]. EVR4 is a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. EVR4 inheritance can be autosomal dominant or recessive. Ref.18 Ref.20 Ref.22 Ref.23 Ref.28 Ref.32 Ref.33Genetic variations in LRP5 are a cause of susceptibility to osteoporosis (OSTEOP) [

MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture. Ref.21 Ref.24 Ref.26Defects in LRP5 are the cause of osteoporosis-pseudoglioma syndrome (OPPG) [

MIM:259770]; also known as osteogenesis imperfecta ocular form. OPPG is a recessive disorder characterized by very low bone mass and blindness. Individualy with OPPG are prone to develop bone fractures and deformations and have various eye abnormalities, including phthisis bulbi, retinal detachments, falciform folds or persistent vitreal vasculature. Ref.14 Ref.22 Ref.27 Ref.29 Ref.30Defects in LRP5 are a cause of high bone mass trait (HBM) [

MIM:601884]. HBM is a rare phenotype characterized by exceptionally dense bones. HBM individuals show otherwise a completely normal skeletal structure and no other unusual clinical findings. Ref.15 Ref.16 Ref.25Defects in LRP5 are a cause of endosteal hyperostosis Worth type (WENHY) [

MIM:144750]; also known as autosomal dominant osteosclerosis. WENHY is an autosomal dominant sclerosing bone dysplasia clinically characterized by elongation of the mandible, increased gonial angle, flattened forehead, and the presence of a slowly enlarging osseous prominence of the hard palate (torus palatinus). Serum calcium, phosphorus and alkaline phosphatase levels are normal. Radiologically, it is characterized by early thickening of the endosteum of long bones, the skull and of the mandible. With advancing age, the trabeculae of the metaphysis become thickened. WENHY becomes clinically and radiologically evident by adolescence, does not cause deformity except in the skull and mandible, and is not associated with bone pain or fracture. Affected patients have normal height, proportion, intelligence and longevity. Ref.17Defects in LRP5 are the cause of osteopetrosis autosomal dominant type 1 (OPTA1) [

MIM:607634]. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA1 is characterized by generalized osteosclerosis most pronounced in the cranial vault. Patients are often asymptomatic, but some suffer from pain and hearing loss. It appears to be the only type of osteopetrosis not associated with an increased fracture rate. Ref.17Defects in LRP5 are the cause of van Buchem disease type 2 (VBCH2)[

MIM:607636]. VBCH2 is an autosomal dominant sclerosing bone dysplasia characterized by cranial osteosclerosis, thickened calvaria and cortices of long bones, enlarged mandible and normal serum alkaline phosphatase levels. Ref.17

Sequence similarities: Belongs to the LDLR family.Contains 4 EGF-like domains.Contains 3 LDL-receptor class A domains.Contains 20 LDL-receptor class B repeats.
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000